title: Disappearance of gadolinium enhancement in a chemoresistant astrocytoma of the tectum after high-dose interferon beta.
abstract: Interferon beta 6 million units per week was administered to a patient with an aggressive astrocytoma in the tectum that was resistant to cisplatin, etoposide, vinblastine, and the oral alkylating agent temozolomide. The tumor was immunopositive for O6-methylguanine-DNA methyltransferase (MGMT). Interferon beta caused the disappearance of the gadolinium-enhanced lesion in the tectum. Interferons have apoptotic and antiangiogenic effects on tumor cells, and the lesion's disappearance may have been induced by complexes of these effects. Administration of interferon beta might have a favorable effect on tectal gliomas that are immunopositive for MGMT and resistant to chemoradiotherapy including temozolomide.
authors.affiliation: Department of Neurosurgery, Teikyo University Chiba Medical Center, Ichihara City, Chiba, Japan. akirakun@med.teikyo-u.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Matsuno
authors.forename: Takamitsu
authors.initials: T
authors.lastname: Fujimaki
authors.forename: Akiko
authors.initials: A
authors.lastname: Mizutani
authors.forename: Fuyuaki
authors.initials: F
authors.lastname: Ide
authors.forename: Hideki
authors.initials: H
authors.lastname: Tanaka
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Asano
authors.forename: Satoru
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Uno
authors.forename: Junichi
authors.initials: J
authors.lastname: Tanaka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakaguchi
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Sasaki
authors.forename: Mineko
authors.initials: M
authors.lastname: Murakami
authors.forename: Kazuto
authors.initials: K
authors.lastname: Yamazaki
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ishida
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003287:Contrast Media; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D007275:Injections, Intravenous; D016899:Interferon-beta / Q000008:administration & dosage*; D008279:Magnetic Resonance Imaging; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics / Q000378:metabolism; D003336:Tectum Mesencephali / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000077204:Temozolomide; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D014747:Vinblastine; D005047:Etoposide; D016899:Interferon-beta; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D019786:Gadolinium DTPA; D002945:Cisplatin; D000077204:Temozolomide